iPS Bio uses GMP‑compliant induced pluripotent stem cell (iPSC) technology to generate patient‑derived neuronal cell lines for both regenerative cell‑gene therapies and precision drug screening. It offers end‑to‑end services—including custom iPSC banking, disease‑specific differentiation, high‑content screening, and AI‑driven analytics—to help pharma, biotech, and academic partners accelerate discovery and development of treatments for neurodegenerative and other intractable neurological diseases.
Funding
$7.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with neurodegenerative and other intractable neurological diseases have few effective treatment options, and drug discovery efforts lack disease-relevant human cellular models, leading to low predictive success and delayed therapy development.
Solution
iPS Bio leverages induced pluripotent stem cell (iPSC) technology to create patient‑derived cell lines for both therapeutic development and precision drug screening. The company generates clinical‑grade iPSC lines, differentiates them into disease‑relevant neuronal cell types, and applies these models in high‑content screening pipelines to identify candidate compounds for conditions such as Huntington’s disease, Alzheimer’s disease, stroke, and other chronic neuro disorders. Parallelly, iPS Bio develops allogeneic and autologous iPSC‑based cell and gene therapies aimed at restoring lost neural function. All processes follow Good Manufacturing Practice (GMP) standards, and the resulting data are integrated into a cloud‑based analytics platform that supports target validation, mechanism‑of‑action studies, and regulatory‑ready documentation. By offering end‑to‑end stem‑cell solutions—from custom iPSC banking to therapeutic candidates—iPS Bio accelerates the translation of regenerative approaches and drug candidates to clinical testing.
Features
- GMP‑compliant generation and banking of personalized iPSC lines using SeV transduction and clonal selection
- Differentiation protocols for disease‑specific neuronal phenotypes (e.g., Huntington’s, Alzheimer’s, stroke) enabling physiologically relevant assays
- High‑content imaging and image‑based high‑throughput screening (HCS) platform for rapid evaluation of compound libraries on patient‑derived cells
- Integrated AI/ML analytics to assess efficacy, toxicity, and mechanism‑of‑action from multi‑modal screening data
- Development of both allogeneic and autologous iPSC‑derived cell and gene therapies targeting neuroregeneration
- Secure cloud dashboard delivering longitudinal assay results, biomarker readouts, and regulatory documentation for partners
- Customizable service contracts for academic, biotech, and pharmaceutical collaborators, including iPSC banking, screening, and therapeutic development